Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | WNT3A | P56704 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.33 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16754310 | 0.88 | WNT3A (0.36) | KDM4EALDH1A1SMN1; SMN2WNT3AHCRTR1 | |
| SCHEMBL16754411 | 0.87 | GRM5 (0.42) | WNT3AHCRTR1ABL1PIM2ROCK1 | |
| SCHEMBL16754299 | 0.87 | GRM5 (0.37) | KDM4EALDH1A1WNT3AHCRTR1MAPK1 | |
| SCHEMBL16754401 | 0.87 | GRM5 (0.37) | KDM4EALDH1A1WNT3AHCRTR1ABL1 | |
| SCHEMBL17778228 | 0.87 | GRM5 (0.37) | KDM4EALDH1A1WNT3AHCRTR1ABL1 | |
| SCHEMBL16249952 | 0.86 | CA2 (0.38) | KDM4ESMN1; SMN2HCRTR1 | |
| SCHEMBL16754477 | 0.86 | WNT3A (0.40) | WNT3AMAPK1GRM5 | |
| SCHEMBL16775775 | 0.86 | PTGDR (0.34) | KDM4EROCK1ROCK2 | |
| SCHEMBL19706206 | 0.86 | CA9 (0.37) | KDM4EALDH1A1ROCK1ROCK2 | |
| SCHEMBL20733238 | 0.85 | HCRTR1 (0.39) | KDM4EALDH1A1WNT3AHCRTR1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190048016-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190048016-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | KDM4E 1291/4885ALDH1A1 1067/4885SMN1; SMN2 1917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.